Why is the London Stock Exchange losing out to the US 
SK Networks Sets Up AI Research Lab in Silicon Valley 
Boeing Experiences Quarterly Revenue Drop Amid Production Challenges, Beat Expectations 
How marketing classes can rescue ‘ugly produce’ from becoming food waste 
Toyota Teams with Tencent, Nissan Joins Forces with Baidu in China AI Drive 
Tesla Cybertruck Hits 1,000-Unit Weekly Production Amid Q1 Financial Shortfalls 
PUMA and Scuderia Ferrari HP Unveil Miami Limited Edition Collection 
Chipotle Scraps Farmesa Fresh Eatery spinoff, Ghost Kitchen Cease Operations 
Tesla Model 3 Performance Eligible for $7,500 Tax Credit, Launches at $53K 
Family farms are fast disappearing: our research shows how young generations can take them up successfully 
Extraordinary Vietnam fraud case exposes the inherent vulnerabilities of banks 
Ferrari F1 Announces Multi-Year Partnership with HP as Title Sponsor 
New Study Reveals Coke, Pepsi, and Nestle as Top Plastic Polluters 
Hybe Accuses ADOR Subsidiary’s CEO of Breach of Trust 
If plastic manufacturing goes up 10%, plastic pollution goes up 10% – and we’re set for a huge surge in production 
Supreme Court appears open to Starbucks’ claims in labor-organizing case 
IBM Acquires HashiCorp, Giving Its Hybrid-Cloud Business a Boost 
SHELTON, Conn., April 05, 2016 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the 15th Annual Needham Healthcare Conference on Tuesday, April 12, 2016, at 10:00 a.m. ET in New York City.
A live webcast of the presentation can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.
INVESTOR CONTACT: Jesse Baumgartner Stern Investor Relations, Inc. 212-362-1200 [email protected] MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 [email protected]
